Overview

This trial is active, not recruiting.

Conditions primary open angle glaucoma, ocular hypertension
Treatments stage 1 - ats907 - dose 1, stage 1 - ats907 - dose 2, stage 1 - ats907 - dose 3, stage 1 - ats907 - dose 4, stage 1 - vehicle, stage 2 - ats907 - dose a - to be selected based on stage 1, stage 2 - ats907 - dose b - to be selected based on stage 1, timoptic
Phase phase 1/phase 2
Sponsor Altheos, Inc.
Start date January 2012
End date December 2012
Trial size 180 participants
Trial identifier NCT01520116, ATS907-201

Summary

This randomized dose-ranging study will evaluate the safety, tolerability, and preliminary efficacy (reduction in intraocular pressure) of multiple dose levels of ATS907, vehicle, or latanoprost in subjects with primary open angle glaucoma or ocular hypertension. In the first portion, approximately 75 subjects will be randomized to receive either ATS907 or vehicle eye drops for up to 28 days, administered both once and twice daily. In the second portion, up to 180 subjects will be randomized to receive either ATS907 or latanoprost for up to 28 days. Plasma pharmacokinetics will also be evaluated during the first portion of the study.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Masking single blind (investigator)
Primary purpose treatment
Arm
(Experimental)
stage 1 - ats907 - dose 1
QD and/or BID dosing for 28 days
(Experimental)
stage 1 - ats907 - dose 2
QD and/or BID dosing for 28 days
(Experimental)
stage 1 - ats907 - dose 3
QD and/or BID dosing for 28 days
(Experimental)
stage 1 - ats907 - dose 4
QD and/or BID dosing for 28 days
(Placebo Comparator)
stage 1 - vehicle
QD and/or BID dosing for 28 days
(Experimental)
stage 2 - ats907 - dose a - to be selected based on stage 1
QD and/or BID dosing for 4 days
(Experimental)
stage 2 - ats907 - dose b - to be selected based on stage 1
QD and/or BID dosing for 4 days
(Active Comparator)
timoptic
0.5%

Primary Outcomes

Measure
Mean Change in Intraocular Pressure from Baseline
time frame: Stage 1: Days 14, 21 and 28; Stage 2: Day 4

Secondary Outcomes

Measure
Observed Intraocular Pressure and % change from Baseline IOP
time frame: Stage 1: Days 0, 1, 4, 14, 21, 28; Stage 2: Days 0, 4
Mean observed, mean change from Baseline and mean % change from Baseline for the mean diurnal IOP
time frame: Stage 1: Days 0, 1, 4, 14, 21, 28; Stage 2: Days 0, 4

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - 18 years of age or greater - Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT) in both eyes - Unmedicated (post-washout) IOP ≥ 23 mm Hg at 2 eligibility visits: 07:00-09:00 hr on Days O and 1 and IOP > 18 mm Hg at 15:00-17:00 on Day 0 (Stage 1) - Unmedicated (post-washout) IOP criteria after wash out < 32 mm Hg OU at all times points (Stage 1) - Unmedicated (post-washout) IOP ≥ 24 mm Hg at 2 eligibility visits: 07:00-09:00 hr on Days O and 1 and IOP > 21 mm Hg at 9:00-17:00 on Day 0 (Stage 2) - Unmedicated (post-washout) IOP criteria after wash out < 36 mm Hg OU at all times points (Stage 2) - Corrected visual acuity in each eye +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200) - Must be willing to discontinue the use of all ocular hypotensive medications in both eyes prior to and during the entire course of the study Exclusion Criteria: - Ophthalmic (in either eye) 1. Glaucoma: pseudoexfoliation, steroid induced, pigment dispersion glaucoma, and or history of angle closure. Previous glaucoma intraocular surgery or glaucoma laser procedures in study eye(s). Prior laser glaucoma surgery is permitted in the non study eye 2. Refractive surgery in study eye (e.g., radial keratotomy, PRK, LASIK, etc.) 3. Cataract surgery and or other intraocular surgery within three months prior to Screening in either eye. 4. History within 3 months prior to Screening of clinically significant moderate or severe chronic or active ocular infection, inflammation, blepharitis, dermatitis, uveitis or conjunctivitis. 5. Clinically significant corneal dystrophy, epithelial and or endothelial disease, corneal irregularities and or scarring such that reliable applanation tonometry would prevented. 6. Contact lens wear during the duration of the study. 7. Clinically significant ocular disease (e.g. diabetic retinopathy, macular degeneration, or uveitis) which might interfere or progress during the study. 8. Central corneal thickness < 480 or > 600 μm in the study eye - Systemic 1. Clinically significant abnormalities in laboratory tests at screening. 2. Clinically significant systemic disease (e.g., uncontrolled diabetes, uncontrolled hyper or hypotension, hepatic, renal, endocrine or cardiovascular disorders). Participation in any investigational study within the past 30 days. 3. Changes of systemic medication that could have a substantial effect on IOP and or systemic blood pressure within 7 days prior to Baseline (Day 0). 4. Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative urine pregnancy test result at the Screening visit and a negative urine and serum pregnancy at Baseline (Day 0) and must not intend to become pregnant during the study

Additional Information

Official title A Phase 1/2a Randomized, Investigator-masked, Placebo- and Active-controlled, Dose-ranging Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension
Trial information was received from ClinicalTrials.gov and was last updated in October 2012.
Information provided to ClinicalTrials.gov by Altheos, Inc..